Skip to content

Plain-English explainer

Compounded Semaglutide vs Wegovy: Safety, Side Effects and Cost

By Published

We keep this plain-English — no jargon, every claim sourced.

On this page

Featured partner

CoreAge Rx

$99/mo flat

Doctor-reviewed semaglutide with one flat price and built-in human support.

Check availability
Category
Telehealth · semaglutide
Pricing
Flat monthly price
Support
Nurse + dietitian consults
Labs
No labs required

Advertising disclosure · we may earn a commission at no extra cost to you.

Partner

Sprout Health

LegitScript-certified compounded semaglutide with a real brand-name Wegovy/Zepbound path and a near-frictionless, often visit-free start.

Compounded from $149/mo · brand path

Check Sprout Health availability

FDA warning letter

The FDA issued a warning letter to Sprout Health Partners LLC dba Sprout Health in September 2025. It is on the public record in the FDA's warning-letter database, which we link rather than summarize. FDA warning-letter database ↗

Compounded semaglutide is cheaper than Wegovy, and when it's made properly it contains the same active molecule. What you give up is the checking: nobody at FDA reviewed that vial before it reached you, and you measure every dose yourself.

That trade can be reasonable. I just want you to make it with your eyes open, so here is what's the same, what's different, and how to check a compounder before you pay.

Is compounded semaglutide the same drug as Wegovy?

The molecule can be the same; the product is not. Wegovy is a finished drug that FDA approved after reviewing its trials and its factory. Compounded semaglutide is mixed by a pharmacy, and FDA says plainly that compounded drugs are not reviewed for safety, effectiveness or quality before they are marketed1.

There's also a trap on the label. Some compounders have used semaglutide sodium or semaglutide acetate. FDA calls these salt forms "different active ingredients" than the approved drug and says it knows of no lawful basis to compound with them1. If your vial or paperwork names a salt, ask for a different source.

WegovyCompounded
FDA-approvedYesNo
Active ingredientSemaglutideSemaglutide base; a salt form is a red flag
How you dosePrefilled penVial and syringe, in units
StrengthIdentical everywhereVaries by pharmacy
Who makes itNovo Nordisk503A pharmacy or 503B facility
Extras addedNoneSometimes B12 or B6 (untested mix)
Self-pay price, October 2026$349/mo (0.25–2.4 mg)$79–$349/mo, typical $199

Are the side effects different?

Mostly no. If the vial really holds semaglutide at the strength on the label, you'll get the same family of side effects as Wegovy: nausea, diarrhea, vomiting and constipation, worst after each dose increase.

The difference is dosing error, and it's a real one. In a July 2024 alert, FDA described patients injecting five to 20 times the intended dose after mixing up units, milliliters and milligrams, sometimes with syringes far bigger than the dose2. A poison-center case series found two people who had taken 10-fold overdoses from compounded vials; all three patients in that report had nausea, vomiting and abdominal pain, mostly lasting days3.

A pen can't do that to you; a vial can. If you go compounded, write your dose in milligrams and units, and check the math against your own vial's strength with our semaglutide units-to-mg converter.

FDA has also heard of compounded semaglutide prescribed above the label's doses or stepped up faster than the label schedule1. If a program wants you to climb faster than every four weeks, ask why.

How many adverse events has FDA logged?

As of May 31, 2026, FDA had received 990 adverse-event reports tied to compounded semaglutide1. Some involved hospitalization after dosing errors1.

Keep that number in proportion. These are voluntary reports, they don't prove the drug caused each problem, and nobody knows how many people used compounded semaglutide in total. What they do show is a steady pattern of the same avoidable mistake: the wrong amount in the syringe.

What does each cost?

OptionMonthly priceNotes
Wegovy pen (NovoCare self-pay)$199 → $349$199 for a new patient's first two fills through December 31, 2026, then $349 at 0.25–2.4 mg
Wegovy HD 7.2 mg$399For people who've tolerated 2.4 mg
Wegovy pill$149–$299$149 at 1.5 mg up to $299 at 9 and 25 mg
Compounded semaglutide, low end$79–$149Bottom quarter of the programs we track
Compounded semaglutide, typical$199Median regular monthly price
Compounded semaglutide, high end$249–$349Top quarter

*Compounded figures are the regular monthly prices (after any intro offer) stated by 39 online programs, each read on the program's own site and dated on the semaglutide price board. Brand prices are NovoCare's published self-pay prices, read October 4, 2026.*

Over a year, the gap is real. Twelve months at the typical compounded price is about $2,388, against about $4,237 for 13 four-week fills of Wegovy at NovoCare's prices. NovoCare's price buys the medicine only, while many compounded programs bundle the prescriber into their monthly figure, so compare the full bill.

How do you tell if a compounder is legitimate?

Start with the type of pharmacy. A 503A pharmacy compounds against a patient-specific prescription and is exempt from FDA's manufacturing-quality rules (CGMP)4. A 503B outsourcing facility is registered with FDA, must follow CGMP, and is inspected by FDA on a risk-based schedule4.

Neither label makes a vial approved. But a program that names its pharmacy and its class gives you someone to check; one that won't gives you nothing. We track which online programs name their pharmacy on the pharmacy disclosure page.

Before you pay

If you decide compounded is right for you, our compounded semaglutide list shows every seller we track with its published price.

When does switching to the brand make sense?

Consider the brand if any of these sounds like you:

  • You've had a dosing scare, or measuring a syringe stresses you out every week.
  • Your program won't name its pharmacy, or your vial lists a salt form.
  • Your insurance now covers Wegovy, or the $349 price fits your budget.
  • You want the 7.2 mg dose, which has its own trial and label.

Don't copy a vial dose straight onto a pen. Ask your prescriber which pen strength matches the milligram dose you're on now, and whether to step down first. The semaglutide dosage chart shows both ladders side by side.

Narrowly. The shortage that made mass compounding legal ended in February 2025, and FDA has since proposed shutting the 503B route for semaglutide. The full timeline is in is compounded semaglutide still legal?.

If you're comparing programs that sell it, the semaglutide provider guide lists them with prices, and partner programs are tagged. For the brand-versus-brand question, see Wegovy vs Zepbound.

A few more quick ones

Is compounded semaglutide as safe as Wegovy?

It hasn't been shown to be. Compounded semaglutide is not FDA-approved or reviewed for quality, and FDA has logged 990 adverse-event reports for it as of May 31, 2026, many tied to dosing errors with vials.

Does compounded semaglutide have different side effects?

Real semaglutide causes the same nausea, diarrhea, vomiting and constipation as Wegovy. The added risk is measuring the wrong dose from a vial, which FDA has seen at five to 20 times the intended amount.

How much cheaper is compounded semaglutide than Wegovy?

The typical regular price among the online programs we track is $199 a month, versus $349 for self-pay Wegovy at NovoCare as of October 2026.

What's the difference between a 503A and a 503B compounder?

A 503A pharmacy compounds for individual prescriptions and is exempt from FDA's manufacturing-quality rules. A 503B outsourcing facility must follow those rules and is inspected by FDA. Neither makes the drug FDA-approved.

Where this comes from

Every claim above traces back to one of these — real studies and official labeling.

  1. U.S. Food and Drug Administration (2026). FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026; adverse-event counts as of May 31, 2026). U.S. Food and Drug Administration (FDA). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  2. U.S. Food and Drug Administration (2024). FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. U.S. Food and Drug Administration (FDA). https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  3. Lambson JE, Flegal SC, Johnson AR. (2023). Administration errors of compounded semaglutide reported to a poison control center-Case series.. Journal of the American Pharmacists Association. https://pubmed.ncbi.nlm.nih.gov/37392810/
  4. U.S. Food and Drug Administration (2024). Human Drug Compounding Laws (sections 503A and 503B of the FD&C Act). U.S. Food and Drug Administration (FDA). https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.